AMEX delisting sends Avitar to OTCBB:
This article was originally published in Clinica
Executive Summary
The American Stock Exchange (AMEX) has struck oral fluid diagnostic developer Avitar off its trading list, after the company failed to comply with the exchange's listing standards. The Canton, Massachusetts firm, which has been suffering net losses over the last five years, said it will be quoted on the Pink Sheets until its stock is listed on the OTC Bulletin Board.